Business Context and Reporting Period
This Form 8-K filing by REGENXBIO Inc. reports a corporate governance event effective as of January 5, 2018. The report was filed on January 11, 2018.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
- Executive Departure: Faraz Ali resigned as Chief Business Officer of REGENXBIO Inc., effective January 5, 2018.
- Separation Agreement: The Company has not entered into a separation agreement with Mr. Ali at the time of filing. If an agreement is executed later, details will be reported subsequently.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies beyond the immediate personnel change.
Investor Verification Checklist
- Verify if a separation agreement with Faraz Ali has been executed since the filing date.
- Confirm the interim or permanent replacement for the Chief Business Officer role.
- Review subsequent filings for any financial impact related to this executive departure.